Project Name：Paroxetine hydrochloride sustained-release enteric-coated tablets 

Registration Classification：6

Formulations and specifications ：Tablets: 12.5mg, 25mg 

Indications：For the treatment of various types of depressions, including depression accompanied by anxiety and reactive depression . Common symptoms of depression : fatigue, sleep disorders , lack of interest and pleasure in daily activities , loss of appetite . After satisfactory results, continuing taking this can prevent the recurrence of depression .

Original Research Company：GlaxoSmithKline 

Progress ：Recently reported to the State Bureau